Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)

Janice P. Dutcher, Jason P. Fine, Robert L. Krigel, Barbara A. Murphy, Paul L. Schaefer, Marc S. Ernstoff, Patrick J. Loehrer

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: Standard therapy for recurrent or metastatic renal carcinoma includes the biologic response modifiers interferon-alpha (IFN-α) and interleukin-2 (IL-2). The response rate for both agents is modest and toxicity is significant. New agents are needed. Interferon-gamma (IFN-γ) is a type II interferon that demonstrated promising activity in renal carcinoma in early clinical trials. In vitro data suggested synergistic activity when IFN-γ was combined with IFN-α. The Eastern Cooperative Oncology Group conducted a randomized phase II trial to confirm the efficacy of IFN-γ as a single agent and to evaluate the efficacy and toxicity of IFN-γ in combination with IFN-α in the treatment of patients with metastatic or recurrent renal carcinomas. Materials and Methods: Ninety-five patients with recurrent or metastatic renal carcinoma were entered on trial. Patients were stratified based on risk assessment using the Elson method. Patients were randomly assigned to receive either IFN-γ 0.1 mg/m2 weekly (arm A) or IFN-γ 0.3 mg/m2 iv daily x 5 every 3 wk plus IFN-α 10 MU/m2 daily (arm B). Treatment efficacy was evaluated every 6 weeks. Results: Toxicity in the arm A was minimal. Significant toxicity was noted in arm B, with four cases of grade 4 neurotoxicity. No responses were seen with IFN-γ alone. Five responses (two CR and three PR) were noted in the combination arm for an overall response rate of 10%. Four of five responders were classified as "good risk." Median survival for arm A was 7.0 mo vs 10.4 mo for arm B. Risk stratification was significant in arm B. Conclusion: IFN-γ at this dose and schedule failed to demonstrate activity in metastatic/recurrent renal carcinoma. The combination of IFN-γ and IFN-α demonstrated a response rate similar to IFN-α alone. There was no evidence of synergy between IFN-γ and IFN-α.

Original languageEnglish (US)
Pages (from-to)271-281
Number of pages11
JournalMedical Oncology
Volume20
Issue number3
DOIs
StatePublished - Oct 10 2003

Fingerprint

Renal Cell Carcinoma
Interferon-alpha
Interferon-gamma
Survival
Therapeutics
Carcinoma
Kidney
Interleukin-2

Keywords

  • Interferon α
  • Interferon γ
  • Renal cell cancer
  • Risk assessment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). / Dutcher, Janice P.; Fine, Jason P.; Krigel, Robert L.; Murphy, Barbara A.; Schaefer, Paul L.; Ernstoff, Marc S.; Loehrer, Patrick J.

In: Medical Oncology, Vol. 20, No. 3, 10.10.2003, p. 271-281.

Research output: Contribution to journalArticle

Dutcher, Janice P. ; Fine, Jason P. ; Krigel, Robert L. ; Murphy, Barbara A. ; Schaefer, Paul L. ; Ernstoff, Marc S. ; Loehrer, Patrick J. / Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). In: Medical Oncology. 2003 ; Vol. 20, No. 3. pp. 271-281.
@article{a626be1ab2cf412b894e5ace7b5cb77b,
title = "Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)",
abstract = "Introduction: Standard therapy for recurrent or metastatic renal carcinoma includes the biologic response modifiers interferon-alpha (IFN-α) and interleukin-2 (IL-2). The response rate for both agents is modest and toxicity is significant. New agents are needed. Interferon-gamma (IFN-γ) is a type II interferon that demonstrated promising activity in renal carcinoma in early clinical trials. In vitro data suggested synergistic activity when IFN-γ was combined with IFN-α. The Eastern Cooperative Oncology Group conducted a randomized phase II trial to confirm the efficacy of IFN-γ as a single agent and to evaluate the efficacy and toxicity of IFN-γ in combination with IFN-α in the treatment of patients with metastatic or recurrent renal carcinomas. Materials and Methods: Ninety-five patients with recurrent or metastatic renal carcinoma were entered on trial. Patients were stratified based on risk assessment using the Elson method. Patients were randomly assigned to receive either IFN-γ 0.1 mg/m2 weekly (arm A) or IFN-γ 0.3 mg/m2 iv daily x 5 every 3 wk plus IFN-α 10 MU/m2 daily (arm B). Treatment efficacy was evaluated every 6 weeks. Results: Toxicity in the arm A was minimal. Significant toxicity was noted in arm B, with four cases of grade 4 neurotoxicity. No responses were seen with IFN-γ alone. Five responses (two CR and three PR) were noted in the combination arm for an overall response rate of 10{\%}. Four of five responders were classified as {"}good risk.{"} Median survival for arm A was 7.0 mo vs 10.4 mo for arm B. Risk stratification was significant in arm B. Conclusion: IFN-γ at this dose and schedule failed to demonstrate activity in metastatic/recurrent renal carcinoma. The combination of IFN-γ and IFN-α demonstrated a response rate similar to IFN-α alone. There was no evidence of synergy between IFN-γ and IFN-α.",
keywords = "Interferon α, Interferon γ, Renal cell cancer, Risk assessment",
author = "Dutcher, {Janice P.} and Fine, {Jason P.} and Krigel, {Robert L.} and Murphy, {Barbara A.} and Schaefer, {Paul L.} and Ernstoff, {Marc S.} and Loehrer, {Patrick J.}",
year = "2003",
month = "10",
day = "10",
doi = "10.1385/MO:20:3:271",
language = "English (US)",
volume = "20",
pages = "271--281",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)

AU - Dutcher, Janice P.

AU - Fine, Jason P.

AU - Krigel, Robert L.

AU - Murphy, Barbara A.

AU - Schaefer, Paul L.

AU - Ernstoff, Marc S.

AU - Loehrer, Patrick

PY - 2003

Y1 - 2003

N2 - Introduction: Standard therapy for recurrent or metastatic renal carcinoma includes the biologic response modifiers interferon-alpha (IFN-α) and interleukin-2 (IL-2). The response rate for both agents is modest and toxicity is significant. New agents are needed. Interferon-gamma (IFN-γ) is a type II interferon that demonstrated promising activity in renal carcinoma in early clinical trials. In vitro data suggested synergistic activity when IFN-γ was combined with IFN-α. The Eastern Cooperative Oncology Group conducted a randomized phase II trial to confirm the efficacy of IFN-γ as a single agent and to evaluate the efficacy and toxicity of IFN-γ in combination with IFN-α in the treatment of patients with metastatic or recurrent renal carcinomas. Materials and Methods: Ninety-five patients with recurrent or metastatic renal carcinoma were entered on trial. Patients were stratified based on risk assessment using the Elson method. Patients were randomly assigned to receive either IFN-γ 0.1 mg/m2 weekly (arm A) or IFN-γ 0.3 mg/m2 iv daily x 5 every 3 wk plus IFN-α 10 MU/m2 daily (arm B). Treatment efficacy was evaluated every 6 weeks. Results: Toxicity in the arm A was minimal. Significant toxicity was noted in arm B, with four cases of grade 4 neurotoxicity. No responses were seen with IFN-γ alone. Five responses (two CR and three PR) were noted in the combination arm for an overall response rate of 10%. Four of five responders were classified as "good risk." Median survival for arm A was 7.0 mo vs 10.4 mo for arm B. Risk stratification was significant in arm B. Conclusion: IFN-γ at this dose and schedule failed to demonstrate activity in metastatic/recurrent renal carcinoma. The combination of IFN-γ and IFN-α demonstrated a response rate similar to IFN-α alone. There was no evidence of synergy between IFN-γ and IFN-α.

AB - Introduction: Standard therapy for recurrent or metastatic renal carcinoma includes the biologic response modifiers interferon-alpha (IFN-α) and interleukin-2 (IL-2). The response rate for both agents is modest and toxicity is significant. New agents are needed. Interferon-gamma (IFN-γ) is a type II interferon that demonstrated promising activity in renal carcinoma in early clinical trials. In vitro data suggested synergistic activity when IFN-γ was combined with IFN-α. The Eastern Cooperative Oncology Group conducted a randomized phase II trial to confirm the efficacy of IFN-γ as a single agent and to evaluate the efficacy and toxicity of IFN-γ in combination with IFN-α in the treatment of patients with metastatic or recurrent renal carcinomas. Materials and Methods: Ninety-five patients with recurrent or metastatic renal carcinoma were entered on trial. Patients were stratified based on risk assessment using the Elson method. Patients were randomly assigned to receive either IFN-γ 0.1 mg/m2 weekly (arm A) or IFN-γ 0.3 mg/m2 iv daily x 5 every 3 wk plus IFN-α 10 MU/m2 daily (arm B). Treatment efficacy was evaluated every 6 weeks. Results: Toxicity in the arm A was minimal. Significant toxicity was noted in arm B, with four cases of grade 4 neurotoxicity. No responses were seen with IFN-γ alone. Five responses (two CR and three PR) were noted in the combination arm for an overall response rate of 10%. Four of five responders were classified as "good risk." Median survival for arm A was 7.0 mo vs 10.4 mo for arm B. Risk stratification was significant in arm B. Conclusion: IFN-γ at this dose and schedule failed to demonstrate activity in metastatic/recurrent renal carcinoma. The combination of IFN-γ and IFN-α demonstrated a response rate similar to IFN-α alone. There was no evidence of synergy between IFN-γ and IFN-α.

KW - Interferon α

KW - Interferon γ

KW - Renal cell cancer

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=0141636459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141636459&partnerID=8YFLogxK

U2 - 10.1385/MO:20:3:271

DO - 10.1385/MO:20:3:271

M3 - Article

C2 - 14514977

AN - SCOPUS:0141636459

VL - 20

SP - 271

EP - 281

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 3

ER -